Patent 12116640 was granted and assigned to Guardant Health on October, 2024 by the United States Patent and Trademark Office.
Disclosed herein are methods, compositions, and devices for use in the early detection of cancer. The methods include preparing cell-free nucleic acid molecules from a subject for sequencing, sequencing a panel of regions in the cell-free nucleic acid molecules, and detecting one or more markers that are indicative of a cancer.